Matches 1 - 50 out of 103 1 2 3 >
Match Document Document Title
7387782 Protein kinase deficient, immunologically active CMVpp65 mutants  
This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity...
7326535 Immunoreactive peptides from Epstein-Barr virus  
Epstein-Barr virus (EBV) specific polypeptides are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment...
7271148 Inhibition of cellular proteases  
The invention provides a method of decreasing viral replication in cells, the method comprising decreasing levels of functional cellular protease in the cells. The invention further provides a...
7208165 Human cytomegalovirus DNA sequences  
Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and compositions for detecting HCMV infections and...
7202331 Therapeutic anti-cytomegalovirus compounds  
The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response...
7192715 Diagnostics and therapy of epstein-barr virus in autoimmune disorders  
Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified...
7147861 Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate  
A method of designing a new anti-CMV drug is disclosed. In one embodiment, the invention comprises (a) analyzing the binding of glycoprotein O to a glycoprotein O receptor and (b) designing a...
7135186 Varicella zoster virus (VZV) immunoreactive protein VP26 and its diagnostic use  
Varicella zoster virus (VZV) inimunoreactive protein VP26 and its diagnostic use are described. The invention relates to immunoreactive peptides which are homologous with the region of amino acid...
7118755 Herpes viruses for immune modulation  
An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response...
7112331 Vaccines against varicella zoster virus gene 63 product  
The present invention relates to compositions for the treatment or prevention of Zoster of individuals infected with Varicella Zoster virus (VZV), and to the prevention and treatment of Varicella...
7063851 Herpes viruses for immune modulation  
A method of stimulating an immune response in a human or animal subject, which method comprises administering to a subject in need thereof an effective amount of an attenuated herpes virus which: ...
7060283 Immunoreactive peptides from Epstein-Barr virus  
Epstein-Barr virus (EBV) specific polypeptides consisting of a series of one to 1000 peptide units selected from the group consisting of peptide units Φ, Γ, Δ and Ω, wherein Φ is 25 amino...
7025968 CMV vaccines  
The invention provides methods and compositions for inhibiting CMV infection and dissemination in an animal, as well as in vitro and in vivo assay systems for identifying such compositions.
6951651 CTL epitope analogs  
We have screened the HCMV-specific T cell clone, 33F4, with a nonamer PS-SCL based on SEQ ID NO: 1, and described a series of analog peptides that are recognized with greater affinity than the...
6946448 In utero oral nucleic acid immunization  
Methods of nucleic acid immunization comprising the in utero delivery of nucleic acid molecules that encode one or more selected antigens to a vertebrate fetus are disclosed.
6936251 Peptide reagent for the detection of human cytomegalovirus (CMV)  
The invention relates to a peptide reagent comprising peptides immunochemically reactive with antibodies to the human cytomegalovirus (CMV). New antibodies directed to said peptides or fragments...
6899884 Vaccine against mumps containing a jeryl-lynn virus strain  
A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus. In a preferred embodiment of the invention the vaccine produces higher...
6884422 Freeze-dried hepatitis A attenuated live vaccine and its stabilizer  
The present invention relates to hepatitis A vaccine, especially to a lyophilized attenuated hepatitis A vaccine which can be stored at ambient temperature for extended periods of time, and to a...
6843997 Variant varicella-zoster viruses and methods of use  
The present invention provides methods directed to detecting antibodies that specifically bind to a varicella zoster polypeptide, detecting the presence of a varicella zoster virus in an animal,...
6843992 Immuno-reactive peptide CTL epitopes of human cytomegalovirus  
The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8 + class I MHC restricted cytotoxic T-lymphocytes...
6740324 Methods and compositions useful for stimulating an immune response  
The invention provides compositions containing modified cytomegalovirus, and methods of using the compositions. In various embodiments, the modifications include adding a heterologous sequence...
6723558 Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses  
Polyenv vaccines are provided that comprise mixtures of at least 4 to about 10,000 different recombinant viruses that each express a different HIV env variant or a portion thereof containing both...
6713296 VZV gene, mutant VZV and immunogenic compositions  
The invention provides for a novel VZV gene, mutant VZV and immunogenic compositions based on such novel genes and mutant VZV. Also provided are proteins, diagnostic assays and methods of producing...
6713070 Viral particles which are released after the infection with the human cytomegalovirus, and the use of said particles as a vaccine  
The invention relates to viral particles which are released by mammal cells after the infection with human cytomegalovirus (HCMV). The invention also relates to particles whose antigenicity has...
6713067 Herpes viruses for immune modulation  
An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response...
6703024 EBV CTL epitopes  
The present invention provides cytotoxic Epstein-Barr virus T-cell epitopes. These epitopes are QVKWRMTTL, VFSDGRVAC, VPAPAGPIV, TYSAGIVQI, LLDFVRFMGV, QNGALAINTF, VSSDGRVAC, VSSEGRVAC, VSSDGRVPC,...
6692749 Non-splicing variants of gp350/220  
Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350...
6635472 Retrovirus and viral vectors  
This invention relates to the fields of genetic engineering, virus replication and gene transfer. More specifically, this invention relates to polynucleotide construct, recombinant virus,...
6632438 Recombinant poxvirus cytomegalovirus, compositions, and uses  
Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the...
6544521 Immunoreactive peptide CTL epitopes of human cytomegalovirus pp150  
The invention provides peptides which are immunogenic epitopes recognized by CD8 + class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent cytomegalovirus (HCMV) infection. The...
6518013 Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission  
Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type...
6506553 Method for diagnosis of Epstein-Barr virus associated disease  
A novel assay utilizing Epstein-Barr virus (EBV) specific peptides is disclosed. The assay is particularly useful for detecting early antigen antibodies in a blood sample from an individual having...
6500663 Unique associated Kaposi's sarcoma virus sequences and uses thereof  
This invention provides an isolated DNA molecule which is at least 30 nucleotides in length and which uniquely defines a herpesvirus associated with Kaposi's sarcoma. This invention provides an...
6495144 EBNA2 peptides and methods of using same  
The present invention provides peptides having substantial homology with the CBF1/RBPJk interaction domain of EBNA2. The peptides preferably comprise between about ten and twenty amino acids. The...
6471965 Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque  
A vaccine is disclosed for the prophylaxis against pathogenic development of atherosclerotic plaque in a mammalian subject susceptible thereto which consists essentially of a multiplicity of killed...
6451320 Combined hepatitis and herpesvirus antigen compositions  
Novel combined vaccine compositions preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in...
6448389 Human cytomegalovirus DNA constructs and uses therefor  
Novel DNA molecules for in vitro and in vivo expression of HCMV gB, gB transmembrane deleted derivatives, pp65, pp150, and IE-exon-4 proteins are described. Preferably, the molecules are plasmids....
6433024 Topical anti-acne composition  
The present invention is directed towards a topical composition for the treatment of acne comprising water, an organic peroxide, an alpha hydroxy acid, a moisturizer, an isosorbide and a detergent....
6432679 Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220  
The present invention provides vaccine adjuvants comprising the Epstein Barr Virus glycoprotein 350/220 or naturally occurring variants thereof, a fusion protein comprising EBV Gp350/220 sequence...
6410704 Methods and compositions for the preparation and use of a herpes protease  
The present invention relates to the identification and purification of a herpes protease and a nucleic acid segment coding for two proteins. The first protein is the herpes protease which is able...
6342229 Herpesvirus particles comprising fusion protein and their preparation and use  
Herpesviral particle preparations, e.g. a preparation of herpesviral particles isolated from the cell culture in which such particles were produced, can have at least part of the VP22 tegument...
6291437 Methods and compositions for retarding the development of atherosclerotic lesions  
A method for preventing or retarding the development atherosclerotic lesions or restenosis involves administering to a subject, preferably a human, an effective amount of an anti-viral composition...
6258363 Varicella zoster virus (VZV) immunoreactive protein VP26 and its diagnostic use  
Varicella zoster virus (VZV) immunoreactive protein VP26 and its diagnostic use are described. The invention relates to immunoreactive peptides which are homologous with the region of amino acid...
6258362 Stabilization of herpes virus preparations  
Stabilized dried pharmaceutical compositions dispersible in aqueous liquid or injection comprise (i) virus e.g. for use as a vaccine or vector, preferably a herpesvirus, e.g. attenuated or...
6242567 Method for detection and prevention of human cytomegalovirus infection  
Disclosed are amino acid sequences of the late 64 kilodalton protein of human cytomegalovirus (HCMVgp64), useful in diagnosing and preventing HCMV infections.
6214354 Method for preventing zoster or alleviating varicella related post-herpetic neuralgia  
Herpes Zoster, or varicella related post herpetic neuralgia is alleviated by immunizing people at risk of developing herpes zoster with varicella zoster virus (VZV) antigen.
6210683 Stabilizers containing recombinant human serum albumin for live virus vaccines  
Compositions are provided for improving the stability of live virus vaccines containing, e.g., live varicella zoster, measles, mumps, and rubella viruses. Such improved stabilizers are aqueous...
6207161 Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides  
Immunogens for use in human cytomegalovirus vaccines or skin tests which comprise human cytomegalovirus matrix proteins or fractions thereof are disclosed. It is also disclosed that such matrix...
6183752 Restenosis/atherosclerosis diagnosis, prophylaxis and therapy  
Disclosed and claimed are compositions and methods for therapy and/or prevention of restenosis and/or atherosclerosis. The compositions can include an agent for decreasing viral load of...
6180369 Varicella-zoster virus antigen  
The present invention relates to the construction of a recombinant plasmid which is capable of expressing a secretory truncated glycoprotein (Tgp) of Varicella-zoster virus (VZV) in mammalian...
Matches 1 - 50 out of 103 1 2 3 >